![Risdiplam clinical development program overview. *Final participant... | Download Scientific Diagram Risdiplam clinical development program overview. *Final participant... | Download Scientific Diagram](https://www.researchgate.net/publication/347158723/figure/fig2/AS:970031785598977@1608285008312/Risdiplam-clinical-development-program-overview-Final-participant-study-numbers.png)
Risdiplam clinical development program overview. *Final participant... | Download Scientific Diagram
![Frontiers | Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment | Pharmacology Frontiers | Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment | Pharmacology](https://www.frontiersin.org/files/Articles/592234/fphar-11-592234-HTML-r1/image_m/fphar-11-592234-g001.jpg)
Frontiers | Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment | Pharmacology
![Genentech's Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 Spinal Muscular Atrophy (SMA) | Business Wire Genentech's Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 Spinal Muscular Atrophy (SMA) | Business Wire](https://mms.businesswire.com/media/20200427005918/en/205253/23/GNE_member_Roche_Logo.jpg)
Genentech's Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 Spinal Muscular Atrophy (SMA) | Business Wire
![Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy | Scientific Reports Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-74346-9/MediaObjects/41598_2020_74346_Fig1_HTML.png)
Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy | Scientific Reports
Express | For children with the most severe SMA, Roche oral innovative therapy has a positive effect for 3 years - laitimes
![A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier - Sturm - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier - Sturm - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/22194ca5-ed3d-4903-8318-36641982d4f0/bcp13786-toc-0001-m.png)
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier - Sturm - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library
Spinal Muscular Atrophy UK - Roche has shared an update on part 2 of the risdiplam FIREFISH clinical trial, which shows significant improvement in survival and motor milestones in infants who have
![Children Treated With Risdiplam Continue Meeting Motor Milestones After 1 Year - Practical Neurology Children Treated With Risdiplam Continue Meeting Motor Milestones After 1 Year - Practical Neurology](https://core4.bmctoday.net/storage/images/NewsTable_NMD_Risdiplam_1627918997.jpg)
Children Treated With Risdiplam Continue Meeting Motor Milestones After 1 Year - Practical Neurology
![Risdiplam clinical development program overview. *Final participant... | Download Scientific Diagram Risdiplam clinical development program overview. *Final participant... | Download Scientific Diagram](https://www.researchgate.net/publication/347158723/figure/fig2/AS:970031785598977@1608285008312/Risdiplam-clinical-development-program-overview-Final-participant-study-numbers_Q640.jpg)
Risdiplam clinical development program overview. *Final participant... | Download Scientific Diagram
![Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam | Drug Metabolism Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam | Drug Metabolism](https://dmd.aspetjournals.org/content/dmd/50/1/65/F2.large.jpg)